Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis

Journal of Neuroimmunology

Volumn 85, Issue 2, 1998, Pages 186-192

  McDonnell, G V ^a   McMillan, S A ^a   Douglas, J P ^a   Droogan, A G ^a   Hawkins, S A ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cerebrospinal fluid; Multiple sclerosis; Primary progressive; Soluble E selectin (sE selectin); Soluble intercellular adhesion molecule 1 (sICAM 1); Soluble vascular cell adhesion molecule 1 (sVCAM 1)

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; L SELECTIN; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

E-SELECTIN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; L-SELECTIN; MULTIPLE SCLEROSIS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0032524504     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00009-5     Document Type: Article

References (28)

1. Calabresi P.A., Tranquill L.R., Dambrosia J.M., Stone L.A., Maloni H., Bash C.N., Frank J.A., McFarland H.F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann. Neurol. 41:1997;669-674.
2. Davie C.A., Barker G.J., Webb S., Tofts P.S., Thompson A.J., Miller D.H., McDonald W.I. A proton spectroscopy study of disability in multiple sclerosis. J. Neurol. 243:1996;S33.
3. Dore-Duffy P., Newman W., Balabanov R., Lisak R.P., Mainolfi E., Rothlein R., Peterson M. Circulating soluble adhesion molecules in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with disease activity. Ann. Neurol. 37:1995;55-62.
4. Droogan A.G., McMillan S.A., Douglas J.P., Hawkins S.A. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. J. Neuroimmunol. 64:1996;185-191.
5. Gearing J.H., Newman W. Circulating adhesion molecules in disease. Immunol. Today. 14:1993;506-512.
6. Giovannoni G., Thorpe J.W., Kidd D., Kendall B.E., Moseley I.F., Thompson A.J., Keir G., Miller D.H., Feldmann M., Thompson E.J. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J. Neurol. Neurosurg. Psychiatry. 60:1996;20-26.
7. Giovannoni G., Lai M., Thorpe J., Kidd D., Chamoun V., Thompson A.J., Miller D.H., Feldmann M., Thompson E.J. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology. 48:1997;1557-1565.
8. Hartung H.P., Reiners K., Michels M., Hughes R.A.C., Heidenreich F., Zielasek J., Enders U., Toyka K.V. Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies. Neurology. 44:1994;1153-1158.
9. Hillert J., Gronning M., Nyland H., Link H., Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 55:1992;887-890.
10. Kidd D., Barker G.J., Tofts P.S., Gass A., Thompson A.J., McDonald W.I.et al. The transverse magnetic decay characteristics of long standing lesions and normal appearing white matter in MS. J. Neurol. 244:1997;125-130.
11. Losseff N.A., Webb S.L., O'Riordan J.I., Page R., Wang L., Barker G.J.et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 119:1996;701-708.
12. Matsuda M., Tsukada N., Miyagi K., Yanagisawa N. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J. Neuroimmunol. 59:1995;35-40.
13. McDonnell, G.V., Hawkins, S.A. An epidemiological study of multiple sclerosis in Northern Ireland. Neurology (in press).
14. Olerup O., Hillert J., Fredrikson S., Olsson T., Kam-Hansen S., Moller E., Carlsson B., Wallin J. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc. Natl. Acad. Sci. USA. 86:1989;7113-7117.
15. Pigott R., Dillon L.P., Hemingway I.H., Gearing A.J.H. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem. Biophys. Res. Commun. 187:1992;584-589.
16. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
17. Revesz T., Kidd D., Thompson A.J., Barnard R.O., McDonald W.I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 117:1994;759-765.
18. Rieckmann P., Nunke K., Burchhardt M., Albrecht M., Wiltfang J., Ulrich M., Felgenhauer K. Soluble intercellular adhesion molecule molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood brain barrier. J. Neuroimmunol. 47:1993;133-140.
19. Rieckmann P., Martin S., Weichselbraun I., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Helwig A., Poser S. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology. 44:1994;2367-2372.
20. Rieckmann P., Altenhofen B., Riegel A., Baudewig J., Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann. Neurol. 41:1997;326-333.
21. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 116:1993;117-134.
22. Schleiffebaum B.O., Spertini O., Tedder T.F. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J. Cell Biol. 119:1992;229-238.
23. Thompson A.J., Kermode A.G., MacManus D.G., Kingsley D.P.E., Kendall B.E., Moseley I.F., McDonald W.I. Pathogenesis of progressive multiple sclerosis. Lancet. 333:1989;1322-1323.
24. Thompson A.J., Kermode A.G., MacManus D.G., Kendall B.E., Kingsley D.P.E., Moseley I.F., McDonald W.I. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 300:1990;631-634.
25. Thompson A.J., Kermode A.G., Wicks D., MacManus D.G., Kendall B.E., Kingsley D.P.E., McDonald W.I. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann. Neurol. 29:1991;53-62.
26. Tsukada N., Matsuda M., Miyagi K., Yanagisawa N. Increased levels of intercellular adhesion molecule molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology. 43:1993;2679-2682.
27. Weinshenker B.G., Bass B., Rice G.P.A., Noseworthy J., Carriere W., Baskerville J.et al. The natural history of multiple sclerosis: a geographically-based study: 1. Clinical course and disability. Brain. 112:1989;133-146.
28. Weinshenker B.G., Santrach P., Schaid D., Rodriguez M. Association between class II major histocompatibility complex polymorphisms and the course of multiple sclerosis. Neurology. 45:1995;A384.